| Mechanisms of Resistance to PD-1 and PD-L1 Blockade |
41 |
| Combinations of Bevacizumab With Cancer Immunotherapy |
32 |
| PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy |
23 |
| PD-1/PD-L1 Axis in Lung Cancer |
14 |
| Antiangiogenic Therapy in Colorectal Cancer |
13 |
| Toxicities Associated With PD-1/PD-L1 Blockade |
13 |
| Clinical Development of PD-1 in Advanced Melanoma |
10 |
| Molecular Profiling of Liquid Biopsy Samples for Precision Medicine |
10 |
| Future of Liquid Biopsies With Growing Technological and Bioinformatics Studies: Opportunities and Challenges in Discovering Tumor Heterogeneity With Single-Cell Level Analysis |
9 |
| Adolescent and Young Adult Cancer Biology |
8 |
| Bevacizumab in Cervical Cancer: 5 Years After |
8 |
| Bevacizumab and Glioblastoma Past, Present, and Future Directions |
7 |
| Challenges of Clinical Management of Adolescent and Young Adults With Bone and Soft Tissue Sarcoma |
7 |
| Cancer Burden in Adolescents and Young Adults A Review of Epidemiological Evidence |
6 |
| Multiple Myeloma, Targeting B-Cell Maturation Antigen With Chimeric Antigen Receptor T-Cells |
6 |
| Visit-to-Visit Hemoglobin A1c Variability Is Associated With Later Cancer Development in Patients With Diabetes Mellitus |
5 |
| Oncofertility Meeting the Fertility Goals of Adolescents and Young Adults With Cancer |
5 |
| Smoldering Multiple Myeloma To Treat or Not to Treat |
5 |
| Circulating Tumor Cells Strategies for Capture, Analyses, and Propagation |
5 |
| Mechanosensitive Ion Channels TRPV4 and P2X7 in Disseminating Cancer Cells |
5 |
| Clinical Development of PD-1 Blockade in Hematologic Malignancies |
4 |
| Phosphatidylinositol 3 Kinase delta Inhibitors Present and Future |
4 |
| Errors in Genetic Testing: The Fourth Case Series |
4 |
| Clinical Applications of Next-Generation Sequencing in Precision Oncology |
4 |
| Models of Care-There Is More Than One Way to Deliver |
4 |
| Basket Trials and the MD Anderson Precision Medicine Clinical Trials Platform |
4 |
| Dynamics and Challenges of Clinical Trials in Adolescents and Young Adults With Cancer |
4 |
| Future Approaches to Precision Oncology-Based Clinical Trials |
4 |
| Cellular Immunotherapy for Multiple Myeloma |
4 |
| Radiotherapy for Hodgkin Lymphoma Reducing Toxicity While Maintaining Efficacy |
4 |
| Data-Powered Participatory Decision Making: Leveraging Systems Thinking and Simulation to Guide Selection and Implementation of Evidence-Based Colorectal Cancer Screening Interventions |
3 |
| Liquid Biopsies and Cancer Immunotherapy |
3 |
| Extracellular Vesicles in Cancer Purpose and Promise |
3 |
| Escape From ALL-CARTaz Leukemia Immunoediting in the Age of Chimeric Antigen Receptors |
3 |
| T-Cell Receptor-Based Immunotherapy for Hematologic Malignancies |
3 |
| Novel Agents in Multiple Myeloma |
3 |
| Combinations of Bevacizumab With Immune Checkpoint Inhibitors in Renal Cell Carcinoma |
3 |
| BCL-2 Inhibitors, Present and Future |
3 |
| Bruton Tyrosine Kinase Inhibitors Present and Future |
3 |
| Targeted Therapy in Chronic Lymphocytic Leukemia |
3 |
| Blocking PD-1/PD-L1 in Genitourinary Malignancies: To Immunity and Beyond |
3 |
| Integrative Medicine Therapies for Pain Management in Cancer Patients |
3 |
| Helping Patients Eat Better During and Beyond Cancer Treatment Continued Nutrition Management Throughout Care to Address Diet, Malnutrition, and Obesity in Cancer |
3 |
| Practical Application of About Herbs Website Herbs and Dietary Supplement Use in Oncology Settings |
2 |
| Relevance of Minimal Residual Disease in the Era of Targeted Agents |
2 |
| Added Value of Whole-Exome and Transcriptome Sequencing for Clinical Molecular Screenings of Advanced Cancer Patients With Solid Tumors |
2 |
| Biostatistical and Logistical Considerations in the Development of Basket and Umbrella Clinical Trials |
2 |
| National Cancer Institute Basket/Umbrella Clinical Trials MATCH, LungMAP, and Beyond |
2 |
| Psychosocial Support in Adolescents and Young Adults With Cancer |
2 |
| From the Broad Phase II Trial to Precision Oncology: A Perspective on the Origins of Basket and Umbrella Clinical Trial Designs in Cancer Drug Development |
2 |
